스마트 이식형 펌프 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the smart implantable pumps market size is expected to grow from USD 2.62 billion in 2025 to USD 2.78 billion in 2026 and is forecast to reach USD 3.74 billion by 2031 at 6.12% CAGR over 2026-2031.

This report is Segmented by Pump Type (Perfusion Pumps, Micro Pumps, Programmable Insulin Pumps, and More), Application (Pain Management, Spasticity Management, Cardiovascular Disorders, and More), End Users (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, and Homecare Settings), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Smart Implantable Pumps Market Trends and Insights

High Prevalence Of Chronic Diseases

Global diabetes prevalence surpassed 537 million adults in 2025, widening the therapeutic field beyond pain management toward insulin, baclofen and chemotherapeutic delivery. Intrathecal baclofen pumps cut spasticity severity by 40.25% in multiple cohort analyses, directly improving motor performance in cerebral palsy. Registry reviews tracking 1,403 oncology cases documented durable pain control over 12 months when implantable systems replaced systemic opioids. Such outcome evidence underpins payer justification and accelerates prescriber confidence, driving incremental Smart implantable pumps market adoption across neurological and oncologic specialties.

Advancements In Closed-Loop & IoT-Enabled Pump Technology

Medtronic's MiniMed 780G delivers >80% Time-in-Range results, surpassing ADA glycemic targets in real-world cohorts. Nevro's HFX iQ integrates adaptive algorithms that tailor spinal stimulation parameters, illustrating the shift toward AI-directed therapy. FDA cybersecurity guidance issued in 2025 codifies secure-by-design principles, giving manufacturers a predictable path to clearance. Interoperability alliances, such as Abbott's global CGM-pump integration deals, future-proof installed bases and extend recurring revenue streams.

Stringent Regulatory Scrutiny & Recall Risk

Section 524B now obliges every cyber-device submission to include a Software Bill of Materials, threat modeling and remediation road map, extending dossier volume and review times. ICU Medical's 2025 warning letter illustrates the financial and reputational cost when legacy infusion platforms fall short of updated standards. Design-control rigor mandated under 21 CFR 820 inflates development budgets but ultimately elevates product reliability. For smaller innovators, capital scarcity heightens acquisition likelihood, nudging the Smart implantable pumps market toward moderate concentration.

Other drivers and restraints analyzed in the detailed report include:

1. Shift To Home-Based And Ambulatory Care
2. Emergence of BioMEMS Nano-Fluidic Micro-Dosing
3. Battery Longevity & Biocompatibility Issues

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The segment generated 41.02% of 2025 revenue from perfusion models, anchoring the Smart implantable pumps market size in inpatient pain therapy. Micro pumps, however, exhibit a 15.88% CAGR that redefines growth math. Their MEMS sensors synchronize real-time flow with sensor feedback, facilitating sub-microliter precision and widening therapeutic scope to gene vectors and biologics. AI-optimized control loops, already standard in hybrid insulin platforms, migrate to micro pump architectures to personalize intra-day dosing. Supply-chain localization and wafer-level manufacturing cut cost curves, lowering entry thresholds for start-ups and thereby diversifying vendor rosters within the Smart implantable pumps market.

Second-generation perfusion units retain surgical mindshare thanks to simple programmability, but predictive maintenance modules now alert clinicians to reservoir depletions and catheter resistance spikes. Drug-eluting and iontronic variants join R&D pipelines, offering infection-mitigation and on-chip sterilization features that could reclaim share from competitive neuromodulation alternatives. As proprietary algorithms accrue real-world data, manufacturers consolidate dataset advantages that complicate late entrant catch-up.

Complete Report Scope:

• By Pump Type
  • Perfusion Pumps
  • Micro Pumps
  • Programmable Insulin Pumps
  • Intrathecal Pumps
  • Drug-Eluting Pumps
• By Application
  • Pain Management
  • Spasticity Management
  • Cardiovascular Disorders
  • Diabetes Management
  • Oncology
  • Others
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Homecare Settings
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America contributed 39.85% of 2025 turnover, underpinned by extensive payer coverage and a robust clinical trial ecosystem. Europe follows with CE solidarity enabling multi-country launches off a single dossier, though slower reimbursement cycles temper early uptake. China's volume-based procurement and indigenous manufacturing grants stimulate local production of programmable pumps, lowering ASPs and broadening domestic access.

Asia-Pacific's 9.18% CAGR arises from demographic aging and chronic disease incidence intersecting with state incentives for smart device localization. India's frugal engineering adapts high-end models into cost-efficient variants suitable for tier-2 city clinics. Partnerships that bundle AI analytics with pump hardware appeal to public-health buyers focused on remote regions, reinforcing digital-health alignment in regional tender criteria.

Regulatory convergence initiatives, such as Singapore's IMDRF leadership, reduce redundant clinical testing and accelerate cross-border registration. Concurrently, cybersecurity stipulations modeled on FDA precedents assure end users of data protection, narrowing the perceived quality gap versus Western imports. Steadily, these dynamics propel Smart implantable pumps market penetration deeper into populous economies while seeding global supply-chain resilience.

1. Medtronic
2. Abbott Laboratories
3. Cognos Therapeutics
4. Insulet
5. Tandem Diabetes Care
6. Intera Oncology
7. i2o Therapeutics
8. OrphaCare GmbH
9. Flowonix Medical
10. Codman & Shurtleff
11. Baxter
12. Boston Scientific
13. Tricumed Medizintechnik
14. Nevro
15. B. Braun
16. Fresenius
17. Advanced Microfluidics SA
18. I-Flow Corporation
19. MicroPort
20. Nano Precision Medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 High Prevalence Of Chronic Diseases
  • 4.2.2 Aging Population & Long-Term Care Burden
  • 4.2.3 Advancements In Closed-Loop & IoT-enabled Pump Technology
  • 4.2.4 Shift To Home-Based And Ambulatory Care
  • 4.2.5 Emergence Of Biomems Nano-Fluidic Micro-Dosing
  • 4.2.6 Cybersecurity-Driven Regulatory Fast-Tracking
• 4.3 Market Restraints
  • 4.3.1 Stringent Regulatory Scrutiny & Recall Risk
  • 4.3.2 Battery Longevity & Biocompatibility Issues
  • 4.3.3 Escalating Cyber-Threat Surface
  • 4.3.4 Limited Implantable-Pump Surgical Expertise
• 4.4 Technological Outlook
• 4.5 Porter's Five Forces
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitute Products
  • 4.5.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Pump Type
  • 5.1.1 Perfusion Pumps
  • 5.1.2 Micro Pumps
  • 5.1.3 Programmable Insulin Pumps
  • 5.1.4 Intrathecal Pumps
  • 5.1.5 Drug-Eluting Pumps
• 5.2 By Application
  • 5.2.1 Pain Management
  • 5.2.2 Spasticity Management
  • 5.2.3 Cardiovascular Disorders
  • 5.2.4 Diabetes Management
  • 5.2.5 Oncology
  • 5.2.6 Others
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Ambulatory Surgical Centers
  • 5.3.3 Specialty Clinics
  • 5.3.4 Homecare Settings
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Medtronic plc
  • 6.3.2 Abbott Laboratories
  • 6.3.3 Cognos Therapeutics
  • 6.3.4 Insulet Corporation
  • 6.3.5 Tandem Diabetes Care
  • 6.3.6 Intera Oncology
  • 6.3.7 i2o Therapeutics
  • 6.3.8 OrphaCare GmbH
  • 6.3.9 Flowonix Medical
  • 6.3.10 Codman & Shurtleff
  • 6.3.11 Baxter International
  • 6.3.12 Boston Scientific Corp.
  • 6.3.13 Tricumed Medizintechnik GmbH
  • 6.3.14 Nevro Corporation
  • 6.3.15 B. Braun Melsungen AG
  • 6.3.16 Fresenius Kabi
  • 6.3.17 Advanced Microfluidics SA
  • 6.3.18 I-Flow Corporation
  • 6.3.19 MicroPort Scientific
  • 6.3.20 Nano Precision Medical

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment